ADARx Pharmaceuticals (NASDAQ:ADRX) Upgraded at UBS Group

ADARx Pharmaceuticals (NASDAQ:ADRX) was upgraded by stock analysts at UBS Group to a “strong-buy” rating in a research note issued to investors on Tuesday, Zacks reports.

Other analysts also recently issued research reports about the stock. Wall Street Zen upgraded shares of ADARx Pharmaceuticals to a “hold” rating in a report on Saturday, October 3rd. TD Cowen began coverage on ADARx Pharmaceuticals in a report on Tuesday. They set a “buy” rating on the stock. Morgan Stanley initiated coverage on ADARx Pharmaceuticals in a report on Tuesday. They set an “overweight” rating and a $32.00 target price on the stock. Finally, JPMorgan Chase & Co. initiated coverage on ADARx Pharmaceuticals in a research report on Tuesday. They issued an “overweight” rating and a $38.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $35.00.

ADARx Pharmaceuticals Price Performance

ADRX opened at $17.68 on Tuesday. ADARx Pharmaceuticals has a twelve month low of $16.61 and a twelve month high of $23.21.

Insider Activity

In other ADARx Pharmaceuticals news, Director Simeon George acquired 1,600,000 shares of the firm’s stock in a transaction that occurred on Monday, September 28th. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $27,200,000.00. Following the completion of the acquisition, the director owned 5,554,094 shares of the company’s stock, valued at approximately $94,419,598. The trade was a 40.46% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, major shareholder Sr One Capital Management, Llc acquired 1,600,000 shares of the stock in a transaction that occurred on Monday, September 28th. The stock was acquired at an average price of $17.00 per share, with a total value of $27,200,000.00. Following the completion of the transaction, the insider directly owned 5,554,094 shares of the company’s stock, valued at $94,419,598. This trade represents a 40.46% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders have bought 3,261,516 shares of company stock valued at $55,445,772.

ADARx Pharmaceuticals Company Profile

ADARx Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing medicines that target disease-driving proteins through RNA-based technologies. The company’s platform is designed to support potent and durable control of protein production, with the goal of creating therapies that may be administered less frequently than conventional treatments.

ADARx is advancing a pipeline of investigational therapeutics for conditions involving the kallikrein-kinin and complement pathways, which are implicated in hereditary angioedema and other immune-mediated or inflammatory diseases.